NTLA Stock Forecast: Intellia Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$10
+5.36% on the day

The 20 Wall Street analysts covering Intellia Therapeutics, Inc. hold a median 12-month price target of $16 — +54.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 27 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.3B
Ticker Nerd rank
27/ 100
Median analyst target
$16
Analysts covering
20
Revenue$7.7M−46.2% y/y
Operating income−$112.8M
Net income−$106.6M
Free cash flow−$84.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.4%
1M
−15.3%
YTD
+11.6%
1Y
+24.8%
From 52W high
−43.8%
From 52W low
+24.8%
$8
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Intellia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
27/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
72
Growth
65
Value
48
Volatility
44
Quality
41
Momentum
37
Revisions
27
Issuance
10

Accruals (72): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NTLA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NTLA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26NTLAHigh $61Median $16Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says20 analysts
10
Buy
6
Hold
4
Sell
$8
Low
$16
Median
$61
High

The green dot is the last close — the median target sits +54.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Oct 2026BarclaysInitiatesUnderweight$8.00
9 Sept 2026CitizensReiteratesMarket Outperform$30
9 Sept 2026HC Wainwright & Co.ReiteratesBuy$25
9 Sept 2026WedbushMaintainsNeutral$12 → $13
25 Aug 2026CitizensReiteratesMarket Outperform$30
7 Aug 2026Evercore ISI GroupUpgradeOutperform$16 → $24
16 July 2026Wolfe ResearchDowngradeUnderperform$9.00
10 July 2026WedbushMaintainsNeutral$12 → $17
16 June 2026Canaccord GenuityMaintainsBuy—
15 June 2026CitizensReiteratesMarket Outperform—
15 June 2026HC Wainwright & Co.ReiteratesBuy—
15 June 2026WedbushReiteratesNeutral—
13 May 2026BernsteinMaintainsMarket Perform—
13 May 2026HC Wainwright & Co.MaintainsBuy—
12 May 2026Canaccord GenuityMaintainsBuy—
12 May 2026WedbushReiteratesNeutral—
28 Apr 2026Canaccord GenuityMaintainsBuy—
28 Apr 2026CitizensMaintainsMarket Outperform—
28 Apr 2026Goldman SachsMaintainsSell—
28 Apr 2026Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NTLA.

Market Radar

This page is one stock. Monday covers all of them.

NTLA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NTLA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Intellia Therapeutics, Inc. returned +24.8% against +6.9% for the S&P 500, dividends included.

NTLA vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200220Jan 26Apr 26Jul 26Oct 26NTLAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NTLA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
6
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
27.0×

Cheaper than 6% of US stocks

Price / book
2.3×

Cheaper than 39% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−48.0%

Higher than 6% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−62.6%

Higher than 19% of US stocks

Return on assets
−29.9%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Intellia Therapeutics, Inc. has a market value of $1.3B and an enterprise value of $1.1B.

  • Revenue in the twelve months to 30 June 2026: $59.5M. The latest quarter shrank 46.2% year on year.

  • Net income over the same four quarters: −$400.0M, a −672.2% net margin.

  • Diluted earnings per share, trailing twelve months: −$3.36.

  • Free cash flow in the twelve months to 30 June 2026: −$348.7M.

  • Shares outstanding: 140.0M.

  • Intellia Therapeutics, Inc. employs 377 people — $158K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

NTLA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NTLAIntellia Therapeutics, Inc.$1.3B27
DMRADamora Therapeutics, Inc.$1.4B44
NRIXNurix Therapeutics, Inc.$1.4B93
TYRATyra Biosciences, Inc.$1.4B28
ANABAnaptysBio, Inc.$1.4B90
VIRVir Biotechnology, Inc.$1.4B95
RAPPRapport Therapeutics, Inc.$1.4B66

Take a look at NTLA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Intellia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NTLA

What is the NTLA stock price forecast for 2026-2027?

The 20 Wall Street analysts covering Intellia Therapeutics, Inc. have a median 12-month price target of $16, with estimates ranging from $8 to $61. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NTLA stock a buy right now?

Of the 20 analysts covering Intellia Therapeutics, Inc., 10 rate it a Buy, 6 a Hold and 4 a Sell. Ticker Nerd's systematic factor model ranks Intellia Therapeutics, Inc. 27 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NTLA?

As at 21 Nov 2026, Intellia Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (72 of 100).

Will NTLA stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +54.5% from the last close, and Ticker Nerd's factor model ranks Intellia Therapeutics, Inc. 27 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NTLA stock forecast for 2030?

No analyst covering Intellia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $61 over the next 12 months.

How has NTLA stock performed over the past year?

Intellia Therapeutics, Inc. returned +24.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Intellia Therapeutics, Inc. do?

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing medicines built on CRISPR/Cas9 technology. Intellia Therapeutics develops both in vivo therapies, which edit genes inside the body, and ex vivo cell therapies, where cells are edited outside the body before being returned to the patient.

Company

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing medicines built on CRISPR/Cas9 technology. Intellia Therapeutics develops both in vivo therapies, which edit genes inside the body, and ex vivo cell therapies, where cells are edited outside the body before being returned to the patient. Its current programs are centered on severe genetic and immune-related diseases, including rare disorders such as transthyretin amyloidosis and hereditary angioedema, as well as selected oncology and autoimmune applications. The company’s broader role in the market is to advance potentially curative treatment approaches that address the root cause of disease rather than symptoms. Intellia Therapeutics operates as a research-driven biopharmaceutical company, with a business model centered on clinical development, collaboration, and platform-based innovation in genetic medicine.

CEO Dr. John M. Leonard M.D. · 377 employees · United States · https://www.intelliatx.com